Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wenwei Ayaranji Tablets
- Development stage
- Phase 3
- Lead developer
- Xinjiang Uygur Pharmaceutical
- Administration
- Oral
01
Overview
Wenwei Ayaranji Tablets is a traditional Uyghur medicine developed by Xinjiang Uygur Pharmaceutical Co., Ltd. for the treatment of functional dyspepsia and appetite loss associated with abnormal gastric mucus syndrome. In the context of Uyghur medicine, the formulation is designed to warm the stomach and regulate the balance of gastric humors (mucus). As of 2023, the drug is undergoing a randomized, double-blind, parallel-group Phase III clinical trial in China to evaluate its efficacy and safety in relieving symptoms such as gastric fullness, pain, and reduced appetite.
- Brand names
- Wenwei Ayaranji Tablets
- Other names
- Wenwei Ayaranji Pian温胃阿亚兰吉片
Beyond the preview
Go deeper on Wenwei Ayaranji Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wenwei Ayaranji Tablets.